Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.
Rodrigo Sánchez-BayonaAlfonso Lopez de SaYolanda Jerez GilarranzAna Sanchez de TorreManuel AlvaIsabel EchavarriaFernando MorenoPablo TolosaBlanca Herrero LopezAlicia de LunaLaura LemaSalvador Gamez CasadoAinhoa MadariagaSara López-TarruellaLuis MansoCoralia Bueno-MuiñoJose A Garcia-SaenzEva CiruelosMiguel MartinPublished in: Breast cancer research and treatment (2024)
This retrospective analysis cohort of everolimus plus ET in mBC patients previously treated with a CDK4/6 inhibitor suggests a longer estimated mPFS when compared with the mPFS with ET monotherapy obtained from current randomized clinical data. Everolimus plus ET may be considered as a valid control arm in novel clinical trial designs.
Keyphrases
- clinical trial
- open label
- end stage renal disease
- newly diagnosed
- double blind
- ejection fraction
- cell cycle
- phase ii
- chronic kidney disease
- prognostic factors
- phase iii
- peritoneal dialysis
- stem cells
- electronic health record
- randomized controlled trial
- study protocol
- bone marrow
- patient reported outcomes
- machine learning
- artificial intelligence
- patient reported